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To the Editor:
The importance of submitting 
data of clinical response to epidermal 
growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) in patients with 
uncommon EGFR mutations has been 
encouraged.1 In view of this, we present 
two cases of a rare EGFR mutation that 
appears to confer resistance to TKIs.
Case 1, a 56-year-old Afro-
Caribbean male presenting with hemop-
tysis, breathlessness, and weight loss. 
Performance status was 1, with no sig-
nificant past medical history and 1 pack 
year smoking history. Imaging showed 
a right middle lobe mass, mediastinal 
lymphadenopathy, and liver metastases. 
Mediastinal biopsy confirmed poorly 
differentiated adenocarcinoma (TTF+, 
CK7+, and CK20−). EGFR mutation 
analysis of selected regions of exons 18 
to 21, using real-time polymerase chain 
reaction, revealed missense mutation in 
exon 20 at nucleotide 2303 resulting in 
serine to isoleucine substitution at codon 
768. After commencing gefitinib 250 mg 
daily, computed tomography scan after 6 
weeks showed disease progression with 
new liver and bony metastases. Within 2 
weeks of switching to 3-weekly peme-
trexed (500 mg/m2) and cisplatin (70 mg/
m2), his exercise tolerance improved and 
imaging after 4 cycles demonstrated a 
partial response. Unfortunately, he was 
admitted to hospital with pneumonia after 
his third cycle of maintenance peme-
trexed (500 mg/m2) and died 4 days later.
Case 2, a 65-year-old Caucasian 
female presenting with acute onset 
shortness of breath. Performance status 
was 0, with no significant past medi-
cal history and 20 pack year smoking 
history. Imaging showed a right lower 
lobe pulmonary embolism with inci-
dental right upper lobe mass, right 
lung metastases, and extensive subcari-
nal, mediastinal, and retroperitoneal 
lymphadenopathy. Mediastinal biopsy 
confirmed poorly differentiated adeno-
carcinoma (TTF+, CK7+, and CK20−). 
EGFR mutation analysis reported 
the same exon 20 missense mutation 
described in case 1.
She had six cycles of pemetrexed 
(500 mg/m2) and cisplatin (70 mg/m2) che-
motherapy with a good partial response. 
Within 2 months of commencing treat-
ment with maintenance erlotinib (150 mg 
daily), imaging showed progression of 
all lesions. Despite early disease stabili-
zation on switching to oral vinorelbine 
(60 mg/m2), computed tomography scan 
after 4 months revealed further progres-
sion. She was unfit for further treatment 
and died 2 months later.
A number of rare EGFR mutations 
exist to which response to targeted therapy 
is unclear. The exon 20 missense mutation 
S768I is one of these. In Asian populations, 
prevalence of this mutation is less than 5% 
although it is more commonly seen in 
combination with other mutations.2 In our 
region, prevalence of this single mutation 
is 1.5% (unpublished data).
In vitro, cells expressing S768I 
mutation are less sensitive to EGFR-
targeted treatment than wild-type cells.3 
However, reports of clinical outcome in 
these patients are conflicting.4,5
Our two cases add to the evidence 
that the S768I mutation causes insensitiv-
ity to TKI therapy. However, both cases 
did show response to platinum-based 
chemotherapy. Furthermore, these cases 
continue to highlight the importance of 
publishing treatment response data for 
cases of rare EGFR mutant lung cancers 
to guide clinical decision making.
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